Literature DB >> 15951630

Case-control study of the muscular compartments and osseous strength in neurofibromatosis type 1 using peripheral quantitative computed tomography.

D A Stevenson1, L J Moyer-Mileur, J C Carey, J L Quick, C J Hoff, D H Viskochil.   

Abstract

Skeletal anomalies are observed in neurofibromatosis type 1 (NF1), but the pathogenesis is unknown. Given that muscle mass is important in the development of the strength of bone, peripheral quantitative computed tomography (pQCT) was utilized to compare measurements of muscle compartments between NF1 individuals and controls. Forty individuals with NF1 (age 5-18 years) were evaluated. Cross-sectional measurements, at the 66% tibial site, were obtained using pQCT (XCT-2000, Stratec) and variables were compared to controls without NF1 ((age 5-18 years, N=380) using analysis-of-covariance controlling for age, height, Tanner stage, and gender. The NF1 cohort showed decreased total cross-sectional area [p<0.001], decreased muscle plus bone cross-sectional area [p<0.001], decreased muscle cross-sectional area [p<0.001], and decreased Stress Strain Index [p=0.010]. These data indicate that NF1 individuals have decreased muscle cross-sectional area and decreased bone strength than individuals without NF1.

Entities:  

Mesh:

Year:  2005        PMID: 15951630

Source DB:  PubMed          Journal:  J Musculoskelet Neuronal Interact        ISSN: 1108-7161            Impact factor:   2.041


  8 in total

1.  Bone resorption in syndromes of the Ras/MAPK pathway.

Authors:  D A Stevenson; E L Schwarz; J C Carey; D H Viskochil; H Hanson; S Bauer; H-Y Cindy Weng; T Greene; K Reinker; J Swensen; R J Chan; F-C Yang; L Senbanjo; Z Yang; R Mao; M Pasquali
Journal:  Clin Genet       Date:  2011-01-19       Impact factor: 4.438

2.  Pediatric 25-hydroxyvitamin D concentrations in neurofibromatosis type 1.

Authors:  David A Stevenson; David H Viskochil; John C Carey; Xiaoming Sheng; Mary Murray; Laurie Moyer-Mileur; Judd Shelton; William L Roberts; Ashley M Bunker; Heather Hanson; Stephanie Bauer; Jacques L D'Astous
Journal:  J Pediatr Endocrinol Metab       Date:  2011       Impact factor: 1.634

3.  Neurofibromin (Nf1) is required for skeletal muscle development.

Authors:  Nadine Kossler; Sigmar Stricker; Christian Rödelsperger; Peter N Robinson; Johnny Kim; Carola Dietrich; Monika Osswald; Jirko Kühnisch; David A Stevenson; Thomas Braun; Stefan Mundlos; Mateusz Kolanczyk
Journal:  Hum Mol Genet       Date:  2011-04-09       Impact factor: 6.150

4.  Tibial geometry in individuals with neurofibromatosis type 1 without anterolateral bowing of the lower leg using peripheral quantitative computed tomography.

Authors:  David A Stevenson; David H Viskochil; John C Carey; Hillarie Slater; Mary Murray; Xiaoming Sheng; Jacques D'Astous; Heather Hanson; Elizabeth Schorry; Laurie J Moyer-Mileur
Journal:  Bone       Date:  2008-12-11       Impact factor: 4.398

5.  Evidence of increased bone resorption in neurofibromatosis type 1 using urinary pyridinium crosslink analysis.

Authors:  David A Stevenson; Elisabeth L Schwarz; David H Viskochil; Laurie J Moyer-Mileur; Mary Murray; Sean D Firth; Jacques L D'Astous; John C Carey; Marzia Pasquali
Journal:  Pediatr Res       Date:  2008-06       Impact factor: 3.756

6.  NF1 is a critical regulator of muscle development and metabolism.

Authors:  Kate Sullivan; Jad El-Hoss; Kate G R Quinlan; Nikita Deo; Fleur Garton; Jane T C Seto; Marie Gdalevitch; Nigel Turner; Gregory J Cooney; Mateusz Kolanczyk; Kathryn N North; David G Little; Aaron Schindeler
Journal:  Hum Mol Genet       Date:  2013-10-24       Impact factor: 6.150

Review 7.  Skeletal muscle and motor deficits in Neurofibromatosis Type 1.

Authors:  M A Summers; K G Quinlan; J M Payne; D G Little; K N North; A Schindeler
Journal:  J Musculoskelet Neuronal Interact       Date:  2015-06       Impact factor: 2.041

Review 8.  The skeletal muscle phenotype of children with Neurofibromatosis Type 1 - A clinical perspective.

Authors:  Amish Chinoy; Grace R Vassallo; Emma Burkitt Wright; Judith Eelloo; Siobhan West; Eileen Hupton; Paula Galloway; Amy Pilkington; Raja Padidela; M Zulf Mughal
Journal:  J Musculoskelet Neuronal Interact       Date:  2022-03-01       Impact factor: 1.864

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.